Hemophilia Market Size, Share, Trends, Demand, Analysis and Forecast 2022-2027

[ad_1]

According to the latest report from the IMARC group “Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The size of the global hemophilia market reached US$10.5 billion in 2021. Looking ahead, IMARC Group expects the market to reach US$20.1 billion by 2027, displaying a CAGR of 11.5% over the period 2022-2027.This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and anyone who is planning to venture into the market in any form.

Hemophilia refers to a rare bleeding disorder in which blood does not clot normally, causing spontaneous or excessive bleeding, even following a minor injury. It is usually hereditary and caused by an inherited lack of a clotting factor that slows down the blood clotting process. It is associated with frequent nosebleeds, easy bruising, bruising, and prolonged bleeding or oozing after injury, surgery, and dental procedures. In severe cases, continuous bleeding can also occur following minor trauma or even in the absence of injury. Although there is currently no cure for hemophilia, the disease can be treated with replacement therapy, medications, and injections of clotting factor or plasma. Hemophilia treatment focuses on replacing the missing protein and preventing complications, which is increasing its demand across the world.

Request a free sample of this report: https://www.imarcgroup.com/hemophilia-market/requestsample

Note: We regularly track the direct effect of COVID-19 on the market, as well as the indirect influence of associated industries. These observations will be incorporated into the report.

Hemophilia Market Trends:

The growing number of hemophilia patients and the rising incidence of genetic abnormalities are the major drivers for the growth of the market. Besides this, increasing diagnosis rates and widespread use of prophylactic treatment for hemophilia are other major factors driving the growth. In addition, government agencies in various countries are launching awareness campaigns on the benefits of early diagnosis and taking favorable initiatives to facilitate early detection of newborns. With this in mind, due to the limited availability of treatment options, governments are increasing support and funding for research and development (R&D) activities to identify therapeutic agents, which positively influences the growth of the market.

Additionally, several key players are focusing on the development of technologically advanced diagnostic tools and therapies to improve the efficiency and accuracy of hemophilia treatment. Along with this, significant investments in the establishment of specialized hemophilia treatment centers (HTCs) have catalyzed the growth of the market. Additionally, the growing number of organizations, such as the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF), that help discover treatments for inherited bleeding disorders and prevent complications through education, research and advocacy, creates a favorable market outlook.

Hemophilia market Report Scope:

Report cover

Details

Market size value in 2021

US$10.5 billion

Market forecast in 2027

US$20.1 billion

Rate of growth

CAGR of 11.5% from 2022 to 2027

Base year for the estimate

2021

Historical data

2016-2021

Forecast period

2022-2027

Breakdown by type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Rupture by treatment:

Rupture by therapy:

  • Replacement therapy
  • ITI Therapy
  • Genetical therapy

Market Breakdown by Region:

  • North America (USA, Canada)
  • Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, others)
  • Middle East and Africa

Competitive landscape with a key player:

  • Baxter International Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • CSL Behring (CSL Limited)
  • F. Hoffmann-La Roche SA
  • Grifols SA
  • Kedrion SpA
  • Novo Nordisk A/S
  • Octapharma S.A.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited.

Main highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Market trends
  • Market drivers and success factors
  • Impact of COVID-19
  • Value chain analysis
  • Complete mapping of the competitive landscape

Ask the analyst for a customization and browse the full report with table of contents and list of figures: https://www.imarcgroup.com/hemophilia-market

As the novel coronavirus (COVID-19) crisis engulfs the world, we continuously monitor changes in markets, as well as industry consumer behaviors around the world and our estimates on the latest market trends and forecasts are made. after considering the impact of this pandemic.

If you want the latest primary and secondary data (2022-2027) with cost module, business strategy, distribution channel, etc. Click request a free sample report, the published report will be emailed to you in PDF format within 24-48 hours of receipt. full payment.

About Us

The IMARC Group is a leading market research firm providing management strategies and market research worldwide. We partner with clients across all industries and geographies to identify their most important opportunities, address their most critical challenges and transform their businesses.

IMARC’s information products include major business, scientific, economic and technological developments for business leaders in pharmaceutical, industrial and high-tech organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverages, travel and tourism, nanotechnology and new processing methods are at the top of the list. company expertise.

Contact us

IMARC Group
30 N Gould St Ste R
Sheridan, Wyoming 82801 USA – Wyoming
E-mail: [email protected]
Such. :(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

[ad_2]
Source link

Comments are closed.